Search

Your search keyword '"Eurocord, Cellular Therapy ' showing total 2 results
Start Over Author "Eurocord, Cellular Therapy Topic bone-marrow-transplantation
2 results on '"Eurocord, Cellular Therapy '

1. Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation

Author

Cunha, Renato, Zago, Marco A, Querol, Sergio, Volt, Fernanda, Ruggeri, Annalisa, Sanz, Guillermo, Pouthier, Fabienne, Kogler, Gesine, Vicario, José L, Bergamaschi, Paola, Saccardi, Riccardo, Lamas, Carmen H, Díaz-de-Heredia, Cristina, Michel, Gerard, Bittencourt, Henrique, Tavella, Marli, Panepucci, Rodrigo A, Fernandes, Francisco, Pavan, Julia, Gluckman, Eliane, Rocha, Vanderson, and Eurocord, Cord Blood Committee Cellular Therapy–Immunobiology Working Party of the European Society for Blood and Marrow Transplantation, Netcord and Faculdade de Medicina de Ribeirão Preto–Faculdade de Medicina de São Paulo, Universidade de São Paulo

Subjects
TIRAP, Male, Transplantation Conditioning, Gene Expression, Biochemistry, HEMATOLOGIC MALIGNANCIES, 0302 clinical medicine, HLA Antigens, VERSUS-HOST-DISEASE, Genotype, Protein Isoforms, CTLA-4 Antigen, Child, Immune response gene, Histocompatibility Testing, Hematology, BIOESTATÍSTICA, Middle Aged, Fetal Blood, TNF-ALPHA, 030220 oncology & carcinogenesis, Cord blood, Child, Preschool, Hematologic Neoplasms, Female, Cord Blood Stem Cell Transplantation, Unrelated Donors, CLINICAL-TRIALS, Adult, Adolescent, Immunology, NLR Proteins, Human leukocyte antigen, Biology, Disease-Free Survival, 03 medical and health sciences, Immune system, Humans, Alleles, Adaptor Proteins, Signal Transducing, Proportional Hazards Models, Retrospective Studies, Polymorphism, Genetic, Umbilical Cord Blood Transplantation, Infant, STEM-CELL TRANSPLANTATION, Cell Biology, CONSENSUS DEVELOPMENT PROJECT, Myeloablative Agonists, BONE-MARROW-TRANSPLANTATION, Transplantation, IDENTICAL SIBLING DONORS, WORKING GROUP-REPORT, Apoptosis Regulatory Proteins, 030215 immunology
Abstract

We evaluated the impact of recipient and cord blood unit (CBU) genetic polymorphisms related to immune response on outcomes after unrelated cord blood transplantations (CBTs). Pretransplant DNA samples from 696 CBUs with malignant diseases were genotyped for NLRP1, NLRP2, NLRP3, TIRAP/Mal, IL10, REL, TNFRSF1B, andCTLA4. HLA compatibility was 6 of 6 in 10%, 5 of 6 in 39%, and >= 4 of 6 in 51% of transplants. Myeloablative conditioning was used in 80%, and in vivo T-cell depletion in 81%, of cases. The median number of total nucleated cells infused was 3.4 x 10(7)/kg. In multivariable analysis, patients receiving CBUs with GG-CTLA4 genotype had poorer neutrophil recovery (hazard ratio [HR], 1.33; P = .02), increased nonrelapse mortality (NRM) (HR, 1.50; P

Published
2017

2. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia

Author

Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, Blaise D, Bosi A, Huang H, Karakasis D, Koc Y, Michallet M, Picardi A, Sanz J, Santarone S, Sengelov H, Sierra J, Vincent L, Volt F, Nagler A, Gluckman E, Ciceri F, Rocha V, Mohty M, Eurocord, Cord Blood Committee of Cellular Therapy and Immunobiology working par, and ALWP-EBMT study

Subjects
RISK ACUTE-LEUKEMIA, hemic and lymphatic diseases, VERSUS-HOST-DISEASE, DONOR TRANSPLANTATION, POSTTRANSPLANTATION CYCLOPHOSPHAMIDE, ENHANCE ENGRAFTMENT, ACUTE MYELOID-LEUKEMIA, BONE-MARROW-TRANSPLANTATION, HEMATOLOGIC MALIGNANCIES, REDUCED-INTENSITY, ACUTE LYMPHOBLASTIC-LEUKEMIA
Abstract

Outcomes after unmanipulated haploidentical stem cell transplantation (Haplo) and after unrelated cord blood transplantation (UCBT) are encouraging and have become alternative options to treat patients with high-risk acute leukemia without human leukocyte antigen (HLA) matched donor. We compared outcomes after UCBT and Haplo in adults with de novo acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Median follow-up was 24 months. Analysis was performed separately for patients with AML, n = 918 (Haplo = 360, UCBT = 558) and ALL, n = 528 (Haplo = 158 and UCBT = 370). UCBT was associated with delayed engraftment and higher graft failure in both AML and ALL recipients. In multivariate analysis, UCBT was associated with lower incidence of chronic graft-vs-host disease both in the AML group (hazard ratio (HR) = 0.63, P = 0.008) and in the ALL group (HR = 0.58, P = 0.01). Not statistically significant differences were observed between Haplo and UCBT for relapse incidence (HR = 0.95, P = 0.76 for AML and HR = 0.82, P = 0.31 for ALL), non-relapse mortality (HR = 1.16, P = 0.47 for AML and HR = 1.23, P = 0.23 for ALL) and leukemia-free survival (HR 0.78, P = 0.78 for AML and HR = 1.00, P = 0.84 for ALL). There were no statistically differences on main outcomes after unmanipulated Haplo and UCBT, and both approaches are valid for acute leukemia patients lacking a HLA matched donor. Both strategies expand the donor pool for patients in need.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results